2021
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021, 81: 1381-1395. PMID: 34297330, DOI: 10.1007/s40265-021-01565-3.Peer-Reviewed Original ResearchConceptsAtrial fibrillationSGLT2 inhibitorsCardiorenal protectionAntiarrhythmic effectsClinical dataSodium/glucose co-transporter-2 inhibitorClinical data implyDate available evidenceGlucose-lowering medicationsEffective therapeutic optionPotential pathophysiological linkLarge clinical trialsPre-specified endpointsType 2 diabetesPossible beneficial effectsPost Hoc AnalysisNormoglycemic adultsAF burdenAF preventionPathophysiologic mechanismsPathophysiological linkSGLT2 inhibitionAntiarrhythmic potentialSodium glucoseTherapeutic optionsAtrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence
Vrachatis DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, Raisakis K, Iliodromitis KE, Reimers B, Stefanini GG, Cleman M, Sianos G, Lansky A, Deftereos SG, Giannopoulos G. Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research And Clinical Practice 2021, 174: 108724. PMID: 33647332, DOI: 10.1016/j.diabres.2021.108724.Peer-Reviewed Original ResearchConceptsDiabetes mellitusAtrial fibrillationType 1 diabetes mellitusIndependent risk factorAtrial fibrillation managementAtrial fibrillation riskAF developmentInsulin deficiencyGlycemic variabilityRisk factorsClinical dataClinical studiesMicrovascular sequelaeAtrial arrhythmogenesisAnimal studiesAtrial myocytesClinical practiceArrhythmia initiationStructural remodelingClinical implicationsT1DMOxidative stressPI3KGlucose transportationMellitus
2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen